ERBB2 and breast carcinoma: While treatment of HER2+ breast cancer with the HER2-targeted monoclonal antibody trastuzumab has demonstrated significant improvements in patient outcome, nearly 70% of patients with HER2+ breast cancer demonstrate resistance to trastuzumab in the metastatic setting [47-49].